CCHT(SZ:000661) Ge Long Hui A P P·2025-10-31 12:57Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd. (referred to as "Jinsai Pharmaceutical"), has received approval from the National Medical Products Administration for clinical trials of its product, GenSci143, in patients with advanced solid tumors [1] Group 1: Product Development - GenSci143 is a first-class therapeutic biological product independently developed by Jinsai Pharmaceutical, intended for the treatment of various advanced solid tumors, including prostate cancer and lung cancer [1] - GenSci143 is a bispecific antibody-drug conjugate (BsADC) targeting B7-H3 and PSMA, which has the potential for both targeted chemotherapy and tumor immunotherapy [1] Group 2: Market Potential - The drug aims to overcome tumor heterogeneity and resistance caused by reduced expression of single targets, thereby covering a broader patient population and producing more durable anti-tumor efficacy [1]